IL6 and COVID-19: Based on these data, a randomized phase II, placebo-controlled study assessed the efficacy of BLD-2660 in hospitalized COVID-19 subjects, assuming its ability to downregulate IL-6 and reduce potential long-term fibrosis and loss of pulmonary function resulting from SARS-CoV pneumonia (NCT04334460) (Table 1).